AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments
In a significant development for the biotechnology sector, AusperBio Therapeutics, Inc., along with its affiliate Ausper Biopharma Co., Ltd., has recently announced the successful closure of an oversubscribed Series B+ financing round that raised an impressive $50 million. This financing, which was spearheaded by an existing prominent venture capital investor, also saw substantial engagement from notable investors such as Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, and Sherpa Capital. This influx of capital comes on the heels of the company's preceding Series B round, completed in December 2024, illustrating the unwavering confidence that investors have in AusperBio's ambitions and progress.
The funds acquired through this financing initiative will play a pivotal role in supporting the ongoing clinical development of AHB-137, which is an innovative unconjugated antisense oligonucleotide (ASO) specifically designed for treating chronic hepatitis B (CHB). The company plans to conduct Phase II trials for AHB-137 outside of mainland China, which is a critical step toward bringing this potential treatment to a broader market.
Dr. Guofeng Cheng, the co-founder and CEO of AusperBio, expressed gratitude towards the investors for their continued trust and engagement, stating, "We are greatly honored by the continued support from our investors. It's a strong vote of confidence in our vision and the progress we've made so far." He further emphasized that the new funding equips the company with the momentum needed to advance AHB-137 into the next phase of global development. The overarching mission of AusperBio revolves around delivering a functional cure for chronic hepatitis B, thereby providing transformative therapies for affected patients globally.
Dr. Chris Yang, co-founder and Chief Scientific Officer, shared insights into the promising progress of AHB-137, particularly highlighting the positive Phase IIb data that was presented at the prestigious EASL Congress held in Amsterdam. With endorsement from the investor community, the AusperBio team is more motivated than ever to continue its clinical efforts and expand the range of treatment options available to individuals living with CHB.
As a clinical-stage biotechnology company, AusperBio is dedicated to advancing innovative therapies using its proprietary Med-Oligo™ ASO technology. This advanced platform has been instrumental in enhancing the therapeutic potential of ASOs, aiding in the fight against chronic diseases, including viral infections, metabolic conditions, and various genetic disorders. Employing a patient-centered innovation approach, AusperBio aims to alleviate the global health burden posed by chronic hepatitis B, which affects millions worldwide.
AHB-137 utilizes a dual-mechanism ASO design, and its clinical advancement showcases compelling data from preclinical and clinical studies that have been presented at significant medical conferences like EASL and AASLD over the past few years. As the company forges ahead, supported by a solid global development strategy, AHB-137 is aligning itself toward the promising possibility of achieving a functional cure for HBV.
AusperBio's steadfast commitment to redefining treatment paradigms for chronic hepatitis B infections underlines their vision of creating a future where patients have access to effective and life-changing therapies. With their recent financial backing, the company is well-positioned to accelerate its development efforts and bring hope to those affected by this persistent illness.
The funds acquired through this financing initiative will play a pivotal role in supporting the ongoing clinical development of AHB-137, which is an innovative unconjugated antisense oligonucleotide (ASO) specifically designed for treating chronic hepatitis B (CHB). The company plans to conduct Phase II trials for AHB-137 outside of mainland China, which is a critical step toward bringing this potential treatment to a broader market.
Dr. Guofeng Cheng, the co-founder and CEO of AusperBio, expressed gratitude towards the investors for their continued trust and engagement, stating, "We are greatly honored by the continued support from our investors. It's a strong vote of confidence in our vision and the progress we've made so far." He further emphasized that the new funding equips the company with the momentum needed to advance AHB-137 into the next phase of global development. The overarching mission of AusperBio revolves around delivering a functional cure for chronic hepatitis B, thereby providing transformative therapies for affected patients globally.
Dr. Chris Yang, co-founder and Chief Scientific Officer, shared insights into the promising progress of AHB-137, particularly highlighting the positive Phase IIb data that was presented at the prestigious EASL Congress held in Amsterdam. With endorsement from the investor community, the AusperBio team is more motivated than ever to continue its clinical efforts and expand the range of treatment options available to individuals living with CHB.
As a clinical-stage biotechnology company, AusperBio is dedicated to advancing innovative therapies using its proprietary Med-Oligo™ ASO technology. This advanced platform has been instrumental in enhancing the therapeutic potential of ASOs, aiding in the fight against chronic diseases, including viral infections, metabolic conditions, and various genetic disorders. Employing a patient-centered innovation approach, AusperBio aims to alleviate the global health burden posed by chronic hepatitis B, which affects millions worldwide.
AHB-137 utilizes a dual-mechanism ASO design, and its clinical advancement showcases compelling data from preclinical and clinical studies that have been presented at significant medical conferences like EASL and AASLD over the past few years. As the company forges ahead, supported by a solid global development strategy, AHB-137 is aligning itself toward the promising possibility of achieving a functional cure for HBV.
AusperBio's steadfast commitment to redefining treatment paradigms for chronic hepatitis B infections underlines their vision of creating a future where patients have access to effective and life-changing therapies. With their recent financial backing, the company is well-positioned to accelerate its development efforts and bring hope to those affected by this persistent illness.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.